Literature DB >> 1373175

Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein.

P Amiguet1, M V Gardinier, J P Zanetta, J M Matthieu.   

Abstract

The myelin/oligodendrocyte glycoprotein (MOG) is found exclusively in the CNS, where it is localized on the surface of myelin and oligodendrocyte cytoplasmic membranes. The monoclonal antibody 8-18C5 identifies MOG. Several studies have shown that anti-MOG antibodies can induce demyelination, thus inferring an important role in myelin stability. In this study, we demonstrate that MOG consists of two polypeptides, with molecular masses of 26 and 28 kDa. This doublet becomes a single 25-kDa band after deglycosylation with trifluoromethanesulfonic acid or peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase, indicating that there are no or few O-linked sugars and that the doublet band represents differential glycosylation. Partial trypsin cleavage, which also gave a doublet band of lower molecular weight, confirmed this idea. MOG was purified by polyacrylamide gel electrophoresis, followed by electroelution. Three N-terminal sequences of eight to 26 amino acids were obtained. By western blot analysis, no binding was found between MOG and cerebellar soluble lectin. MOG does not seem to belong to the signal-transducing GTP-binding proteins. Reduced MOG concentrations were observed in jimpy and quaking dysmyelinating mutant mice, giving further support to its localization in compact myelin of the CNS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373175     DOI: 10.1111/j.1471-4159.1992.tb10040.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

1.  Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies.

Authors:  J Fisher; H Levkovitch-Verbin; H Schori; E Yoles; O Butovsky; J F Kaye; A Ben-Nun; M Schwartz
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 2.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.

Authors:  A Ben-Nun; I Mendel; R Bakimer; M Fridkis-Hareli; D Teitelbaum; R Arnon; M Sela; N Kerlero de Rosbo
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 4.  Glycoproteins of myelin sheaths.

Authors:  R H Quarles
Journal:  J Mol Neurosci       Date:  1997-02       Impact factor: 3.444

5.  Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes.

Authors:  Malabendu Jana; Kalipada Pahan
Journal:  Free Radic Biol Med       Date:  2005-09-15       Impact factor: 7.376

6.  Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation.

Authors:  Tim R Mercer; Irfan A Qureshi; Solen Gokhan; Marcel E Dinger; Guangyu Li; John S Mattick; Mark F Mehler
Journal:  BMC Neurosci       Date:  2010-02-05       Impact factor: 3.288

7.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

8.  Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex.

Authors:  D Pham-Dinh; M G Mattei; J L Nussbaum; G Roussel; P Pontarotti; N Roeckel; I H Mather; K Artzt; K F Lindahl; A Dautigny
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

Review 9.  Novel oligodendrocyte transmembrane signaling systems. Investigations utilizing antibodies as ligands.

Authors:  C A Dyer
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

10.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.